ClinicalTrials.gg
CompletedNCT03901105Updated Aug 28, 2020Results posted

Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

A Phase 3 interventional study of flortaucipir F18 and Brain PET Scan in Alzheimer Disease, sponsored by Avid Radiopharmaceuticals. Completed at 1 site in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-08-28.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
4th of 22
205 · median 70
Started
2019
with 2 others
Phase 3
3 of 22
none open now
Registered
19th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 19th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Scan Reader Criteria (5 total readers):

  • Board-certified in radiology or nuclear medicine
  • Professional experience interpreting PET scans

Scan Criteria (205 total scans):

  • Former enrollment in AZES Study
  • Flortaucipir scan at baseline
  • clinical dementia rating - sum of boxes (CDR-SB) assessment at 18 months

Scan Study Population (AZES Study):

  • 55 to 85 years
  • MCI due to AD or probable AD by National Institute on Aging-Alzheimer's Association criteria (Albert 2011
  • mini-mental status exam () of 20 to 30 inclusive
  • CDR global score of 0.5 (MCI), or 0.5 or 1 (AD) with a memory box score ≥ 0.5, and a score of ≤85 on the Delayed Memory Index of the Repeatable Battery for the Assessment of Neuropsychological Status.
  • Amyloid positive status confirmed by florbetapir PET or lumbar puncture
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Flortaucipir PET Scan

    No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.

    Drug: flortaucipir F18 · Procedure: Brain PET Scan

Interventions

  • No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748

  • ProcedureBrain PET Scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Risk Ratio for AD Symptom Progression on CDR-SB

    Baseline flortaucipir F 18 PET imaging results were determined by majority read (see Baseline Characteristics for description). Clinically meaningful deterioration (CMD) was defined for the primary endpoint as a worsening of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score of one point or more. The clinical dementia rating (CDR) examines 6 categories of cognitive functioning domains. Each domain is scored on a scale ranging from 0 to 3 (including 0.5). A CDR-SB was generated as the sum of the values in each of the 6 domains. The CDR-SB sum scores range from 0 to 18, with higher scores indicating greater cognitive impairment and a 1 point worsening is considered a clinically significant symptom change.

    Time frame: Within 18 months of scan

Secondary outcomes

  1. Risk Ratio for AD Symptom Progression on Various Clinical Measures

    Baseline flortaucipir F 18 PET imaging results were determined by majority read (see Baseline Characteristics for description). Clinically meaningful deterioration (CMD) was defined for the cognitive endpoints as follows: mini-mental status exam (MMSE) worsening of 3 points or greater, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) worsening of 4 points or greater, Pfeffer's Functional Activities Questionnaire (FAQ) worsening of 3 points or greater, CDR global worsening of greater than 0 points. MMSE scores range from 0 to 30 with lower scores indicating worsening cognitive function. ADAS-Cog11 scores range from 0 to 70 with higher scores indicating worsening cognitive function. FAQ scores range from 0 to 30 with higher scores indicating worsening cognitive function. CDR global is scored on a 5 point scale (0, 0.5, 1, 2, 3) with higher scores indicating worsening cognitive function.

    Time frame: Within 18 months of scan

  2. Mean Change in Cognitive/Functional Assessments

    Mean change in cognitive/functional measures baseline between τAD++ and non-τAD++ (determined by baseline tau status), calculated by Mixed Model Repeat Measures (MMRM). CDR-SB scores range from 0 to 18, with higher scores indicating worsening cognitive impairment. MMSE scores range from 0 to 30 with lower scores indicating worsening cognitive function. ADAS-Cog11 scores range from 0 to 70 with higher scores indicating worsening cognitive function. FAQ scores range from 0 to 30 with higher scores indicating worsening cognitive function.

    Time frame: baseline and 18 months

  3. Inter-Reader Reliability of Reader Interpretation of Flortaucipir F 18 PET Imaging

    As measured by Fleiss' Kappa across all scans read. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from -1 to 1 with 1 indicating perfect agreement between the readers. Read results binarized as τAD++ or non-τAD++.

    Time frame: baseline scan

07

Results

Posted Aug 28, 2020

Participant flow

Scans were acquired from subjects previously enrolled in the AZES (NCT02245737) PET substudy (N=205), including mild AD (n=141) and mild cognitive impairment (MCI) due to AD (n=64).

Participant flow — Overall Study
MilestoneAll Subjects
Started205
Completed205
Not completed0

Outcome measures

PrimaryRisk Ratio for AD Symptom Progression on CDR-SB

Baseline flortaucipir F 18 PET imaging results were determined by majority read (see Baseline Characteristics for description). Clinically meaningful deterioration (CMD) was defined for the primary endpoint as a worsening of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score of one point or more. The clinical dementia rating (CDR) examines 6 categories of cognitive functioning domains. Each domain is scored on a scale ranging from 0 to 3 (including 0.5). A CDR-SB was generated as the sum of the values in each of the 6 domains. The CDR-SB sum scores range from 0 to 18, with higher scores indicating greater cognitive impairment and a 1 point worsening is considered a clinically significant symptom change.

Time frame:
Within 18 months of scan
Reported as:
Count of participants · Participants
Risk Ratio for AD Symptom Progression on CDR-SB
ParticipantsCMD (CDR-SB Change >=1)No CMD
tAD++11943
tAD+105
tAD-1414
Statistical analysis
  • CMD (CDR-SB Change >=1) vs No CMD · log linear model · p = 0.0313 (A priori threshold was two-sided 0.05.) · Risk ratio (rr): 1.36 · 95% CI 1.028 to 1.785τAD++ scans represent the numerator for risk, and τAD+/τAD- scans represent the denominator
SecondaryRisk Ratio for AD Symptom Progression on Various Clinical Measures

Baseline flortaucipir F 18 PET imaging results were determined by majority read (see Baseline Characteristics for description). Clinically meaningful deterioration (CMD) was defined for the cognitive endpoints as follows: mini-mental status exam (MMSE) worsening of 3 points or greater, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) worsening of 4 points or greater, Pfeffer's Functional Activities Questionnaire (FAQ) worsening of 3 points or greater, CDR global worsening of greater than 0 points. MMSE scores range from 0 to 30 with lower scores indicating worsening cognitive function. ADAS-Cog11 scores range from 0 to 70 with higher scores indicating worsening cognitive function. FAQ scores range from 0 to 30 with higher scores indicating worsening cognitive function. CDR global is scored on a 5 point scale (0, 0.5, 1, 2, 3) with higher scores indicating worsening cognitive function.

Time frame:
Within 18 months of scan
Reported as:
Count of participants · Participants
Risk Ratio for AD Symptom Progression on Various Clinical Measures
ParticipantsCMD YesNo CMD
MMSE — tAD++11249
MMSE — tAD+68
MMSE — tAD-1513
ADAS-Cog — tAD++9859
ADAS-Cog — tAD+68
ADAS-Cog — tAD-820
FAQ — tAD++11147
FAQ — tAD+95
FAQ — tAD-1414
CDR Global — tAD++7191
CDR Global — tAD+78
CDR Global — tAD-919
Statistical analysis
  • CMD Yes vs No CMD · log linear model · p = .0833 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.) · Risk ratio (rr): 1.35 · 95% CI 0.962 to 1.886τAD++ scans represent the numerator for risk, and τAD+/τAD- scans represent the denominator
  • CMD Yes vs No CMD · log linear model · p = .0141 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.) · Risk ratio (rr): 1.77 · 95% CI 1.122 to 2.796τAD++ scans represent the numerator for risk, and τAD+/τAD- scans represent the denominator
  • CMD Yes vs No CMD · log linear model · p = .0639 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.) · Risk ratio (rr): 1.32 · 95% CI 0.984 to 1.776τAD++ scans represent the numerator for risk, and τAD+/τAD- scans represent the denominator
  • CMD Yes vs No CMD · log linear model · p = .2814 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.) · Risk ratio (rr): 1.28 · 95% CI 0.815 to 2.020τAD++ scans represent the numerator for risk, and τAD+/τAD- scans represent the denominator
SecondaryMean Change in Cognitive/Functional Assessments

Mean change in cognitive/functional measures baseline between τAD++ and non-τAD++ (determined by baseline tau status), calculated by Mixed Model Repeat Measures (MMRM). CDR-SB scores range from 0 to 18, with higher scores indicating worsening cognitive impairment. MMSE scores range from 0 to 30 with lower scores indicating worsening cognitive function. ADAS-Cog11 scores range from 0 to 70 with higher scores indicating worsening cognitive function. FAQ scores range from 0 to 30 with higher scores indicating worsening cognitive function.

Time frame:
baseline and 18 months
Reported as:
Least squares mean · units on a scale
Mean Change in Cognitive/Functional Assessments
units on a scaleτAD++ Scan ResultNon-τAD++ Scan Result
CDR-SB2.22 ± 0.2151.31 ± 0.379
MMSE-4.89 ± 0.377-2.12 ± 0.647
ADAS-Cog116.53 ± 0.6601.97 ± 1.181
FAQ5.22 ± 0.5372.68 ± 0.895
Statistical analysis
  • τAD++ Scan Result vs Non-τAD++ Scan Result · Mixed Models Analysis · p = .0305 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.)Adjusted for baseline clinical score, age, years of education (categorical), and treatment arm (lanabecestat - 20mg or 50mg - or placebo).
  • τAD++ Scan Result vs Non-τAD++ Scan Result · Mixed Models Analysis · p = <0.0001 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.)Adjusted for baseline clinical score, age, years of education (categorical), and treatment arm (lanabecestat - 20mg or 50mg - or placebo).
  • τAD++ Scan Result vs Non-τAD++ Scan Result · Mixed Models Analysis · p = 0.0006 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.)Adjusted for baseline clinical score, age, years of education (categorical), and treatment arm (lanabecestat - 20mg or 50mg - or placebo).
  • τAD++ Scan Result vs Non-τAD++ Scan Result · Mixed Models Analysis · p = 0.0097 (A priori threshold was two-sided 0.05. No adjustment for multiple comparisons.)Adjusted for baseline clinical score, age, years of education (categorical), and treatment arm (lanabecestat - 20mg or 50mg - or placebo).
SecondaryInter-Reader Reliability of Reader Interpretation of Flortaucipir F 18 PET Imaging

As measured by Fleiss' Kappa across all scans read. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from -1 to 1 with 1 indicating perfect agreement between the readers. Read results binarized as τAD++ or non-τAD++.

Time frame:
baseline scan
Reported as:
Number · kappa coefficient
Inter-Reader Reliability of Reader Interpretation of Flortaucipir F 18 PET Imaging
kappa coefficientAll Subjects/All Readers
Inter-Reader Reliability of Reader Interpretation of Flortaucipir F 18 PET Imaging0.754 (0.711 to 0.797)

Adverse events

Collected over Not applicable, as no new patients received treatment as part of this study.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm, Randomly Sequenced Flortaucipir F18 Scans———

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Scans
Mean71.0 ± 7.74
Sex: Female, Male
Sex: Female, Male(Participants)All Scans
Female100
Male105
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Scans
American Indian or Alaska Native0
Asian27
Native Hawaiian or Other Pacific Islander0
Black or African American5
White172
More than one race0
Unknown or Not Reported1
Flortaucipir PET Scan Result
Flortaucipir PET Scan Result(Participants)All Scans
tAD++162
tAD+15
tAD-28
Mean CDR-SB
Mean CDR-SB(units on a scale)All Scans
Mean3.69 ± 1.475
08

Study locations

1 site
  • American College of Radiology
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Lu M, Pontecorvo MJ, Devous MD Sr, Arora AK, Galante N, McGeehan A, Devadanam C, Salloway SP, Doraiswamy PM, Curtis C, Truocchio SP, Flitter M, Locascio T, Devine M, Zimmer JA, Fleisher AS, Mintun MA; AVID Collaborators. Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. JAMA Neurol. 2021 Apr 1;78(4):445-453. doi: 10.1001/jamaneurol.2020.5505. PubMed 33587110 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2019, 1 month.

Results were first posted in Aug 2020, 1 year 4 months after primary completion. A results delay was requested in Jan 2020.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 1 month is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Apr 3, 2019
StartActual
Mar 28, 2019
Primary completionActual
Apr 28, 2019
CompletionActual
Apr 28, 2019
Results delay requested
Jan 22, 2020
Results first posted
Aug 28, 2020
Last update
Aug 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03901105
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
Mar 28, 2019
Primary completion
Apr 28, 2019
Completion
Apr 28, 2019
Results posted
Aug 28, 2020
Last update
Aug 28, 2020

Study contacts

Study Director
study director · Avid Radiopharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion